IDYA IDEAYA Biosciences, Inc.
$37.59▲ +0.37%
Healthcare
Other
After hours
$37.59▲ +0.00%
Sep 11, 7:30 PM ET
Volume 429.2K
Avg Volume (10D) 643.7K
Key Metrics & Fundamentals
Market Cap
$3.63B
P/E Ratio
–
Div Yield
–%
52W Range
24.24 - 42.68
% vs 50 MA
-0.26%
% vs 200 MA
11.13%
RSI-14
43.6
MACD Histogram
-0.4600
Beta (1Y vs SPY)
1.02
Free Cash Flow
-$89.08M
Gross Rev
$8.86M
Gross Profit
$8.86M
EBITDA
-$121.17M
COGS
–
Operating Exp
$131.15M
Operating Income
-$122.29M
EBIT
-$122.29M
Pretax Income
-$112.45M
Net Income
-$112.45M
EPS (Diluted)
-1.22
Price & Volume History
Loading chart…
Recent News
Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial
MT Newswires · Sep 9, 2026 10:53 AM
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
PR Newswire · Sep 9, 2026 10:00 AM
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
PR Newswire · Sep 1, 2026 10:00 AM
Sector Update: Healthcare Stocks Fall Premarket Monday
MT Newswires · Aug 31, 2026 1:19 PM
IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy
MT Newswires · Aug 31, 2026 10:30 AM
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
PR Newswire · Aug 31, 2026 10:00 AM
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Aug 28, 2026 10:00 AM
Sector Update: Healthcare Stocks Higher in Wednesday Trading
MT Newswires · Aug 19, 2026 1:43 PM
Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial
MT Newswires · Aug 19, 2026 10:45 AM
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
PR Newswire · Aug 19, 2026 10:00 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See IDYA's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.